Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VeriFone (PAY), Genesco (GCO): Analysts Slashed Their Price Targets On These 5 Stocks Last Week

Page 1 of 2

Although the fundamental prospects for many companies are strong given the robust U.S. economy and low unemployment rate, some analysts became quite a bit less bullish on several companies last week.

AbbVie Inc (NYSE:ABBV), Genesco Inc. (NYSE:GCO), VeriFone Systems Inc (NYSE:PAY), Computer Programs & Systems, Inc. (NASDAQ:CPSI), and Corrections Corp Of America (NYSE:CXW) were among the companies whose price targets were slashed by at least one analyst firm last week. In this article, we’ll examine why the analysts cut their target marks on these stock and use the latest SEC filings to determine whether the smart money agrees or disagrees with them.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

jail-cells-429638_1920

AbbVie Downgraded

According to Marketbeat, analysts at Credit Suisse slashed their price target on AbbVie Inc (NYSE:ABBV) to $64.03 per share from $82 last week. Sentiment towards many big Pharma stocks has turned negative due to the Mylan NV (NASDAQ:MYL) EpiPen controversy, in which Mylan has raised the price of the essential medication by 4-fold since 2007. The controversy has renewed concerns over future drug pricing and greater industry regulation. Our data shows that hedge funds became a tad less bullish on AbbVie in the second quarter. Out of the 749 hedge funds that we track which filed 13F’s for the June quarter, 57 were long AbbVie Inc (NYSE:ABBV) at the end of June, down by eight funds from the end of the previous quarter.

Follow Abbvie Inc. (NYSE:ABBV)
Trade (NYSE:ABBV) Now!

Weak Comps Sink Genesco 

Analysts at Baird weren’t fans of Genesco Inc. (NYSE:GCO) last week, as the firm cut its price target on the retailer to $53 per share from $80. The price cut followed a disappointing second quarter earnings release issued by Genesco Inc. (NYSE:GCO) on September 1, in which the retailer reported that comparable-store sales fell by 2% company-wide and that its Journeys Group comparable-store sales retreated by 4% year-over-year. Guidance was weak too, as Genesco’s management expects full-year 2016 comparable-store sales to decline in the low-single-digit range. The analysts said that “the stunning comps falloff at Journeys provides too many uncertainties related to the timing and shape of a recovery.” Not many hedge funds owned Genesco in the second quarter. According to our records, 11 funds that Insider Monkey tracks had a bullish position in Genesco Inc. (NYSE:GCO) at the end of June, down by three from the end of March.

Follow Genesco Inc (NYSE:GCO)
Trade (NYSE:GCO) Now!

On the next page we’ll examine why analysts slashed their price targets on VeriFone Systems, Computer Programs & Systems, and Corrections Corp Of America last week.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!